Eli Lilly receives FDA approval for weekly insulin treatment Onswik
Eli Lilly (LLY) has received U.S. Food and Drug Administration (FDA) approval for its once-weekly basal insulin product, Onswik, intended for adults with type 2 diabetes to manage high blood sugar when combined with diet and exercise. This development marks a significant advancement in diabetes treatment by offering patients the convenience of weekly dosing instead of daily injections. The FDA's decision supports Lilly’s ongoing efforts to innovate within the insulin market and improve patient adherence through simplified regimens. Onswik is part of Eli Lilly’s broader portfolio aimed at addressing unmet medical needs, particularly for chronic conditions like diabetes.
Tickers: $LLY